We seek to identify the viral and host genes that govern the target cell specificity and host susceptibility to tumor induction by Abelson murine leukemia virus. To identify the viral genes that govern target cell phenotype we will construct recombinant genomes carrying A-MuLV sequences and the LTR sequences of Friend MuLV, an erythroleukemogenic virus; MCF 247, a thymotropic, lymphomagenic MCF MuLV; and AKV, a non-lymphomagenic, ecotropic MuLV. Viruses will be recovered and tested for their activity in appropriate mice. To identify host genes that govern tissue specificity we will exploit our recent observation that C57BL/6 (B6) mice rapidly developed thymomas when injected intrathymically with A-MuLV, whereas BALB/c mice developed non-thymic pre-B cell lymphomas when infected intrathymically. The disease patterns of recombinant inbred strains made between BALB/c and B6 will be investigated, and the resulting tumor phenotypes determined using serological markers and molecular probes to the T-cell receptor and immunoglobulin loci. We will also attempt to develop an in vitro thymocyte transformation assay. Examination of the DNA of 15 primary non-thymic lymphomas induced by A-MuLV indicated that a major proportion of the tumor cell population derived from very few initially infected cells because simple patterns of provirus intergration were found. We seek to determine the mechanism of this clonal dominance by determining the efficiency of in vivo infection at times after infection, and by determining if multiple independently infected clones of transformed cells exist prior to tumor emergence. Secondary events that might provide selective advantages to A-MuLV transformed cells will be investigated by examination of the expression of known cellular oncogenes in primary A-MuLV tumors cells. Non-v-abl transforming genes found in the DNA of A-MuLV lines and primary tumors will be molecularly cloned and analyzed. The activity of these genes and A-MuLV will be investigated in non-tumorigenic, IL-3 dependent, pre-B cell clones.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Virology Study Section (EVR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Medicine
United States
Zip Code
Largaespada, D A; Kaehler, D A; Mishak, H et al. (1992) A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene 7:811-9
Holland, G D; Ito, K; Kaehler, D A et al. (1991) Thymic targets for Abelson murine leukemia virus are early gamma/delta T lymphocytes. Proc Natl Acad Sci U S A 88:3700-4
Holland, G D; Henkemeyer, M J; Kaehler, D A et al. (1990) Conservation of function of Drosophila melanogaster abl and murine v-abl proteins in transformation of mammalian cells. J Virol 64:2226-35
Green, P L; Kaehler, D A; Bennett, L M et al. (1989) Multiple steps are required for the induction of tumors by Abelson murine leukemia virus. J Virol 63:1989-94
Risser, R; Holland, G D (1989) Structures and activities of activated abl oncogenes. Curr Top Microbiol Immunol 147:129-53
Green, P L; Kaehler, D A; McKearn, J et al. (1988) Substitution of the LTR of Abelson murine leukemia virus does not alter the cell type of virally induced tumors. Oncogene 2:585-92
Risser, R; Green, P L (1988) Abelson virus: current status of a viral oncogene. Proc Soc Exp Biol Med 188:235-42
Green, P L; Kaehler, D A; Risser, R (1987) Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus. Proc Natl Acad Sci U S A 84:5932-6
Green, P L; Kaehler, D A; Risser, R (1987) Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J Virol 61:2192-7
Green, P L; Holland, G D; Kaehler, D et al. (1986) Determinants of Abelson murine leukemia virus pathogenesis. Curr Top Microbiol Immunol 132:62-74

Showing the most recent 10 out of 11 publications